Scientists in the UK are seeking recruiting thousands of teenagers (presumably with hiring) to help them debate a debate about whether vaccinations for a particular type of meningitis are widely used should.
The nationally funded study coined the adolescents against meningitis or TEAM, trial, will live 24,000 teenagers 16 to 18 years old in 14 cities across the country. They are randomly divided into three groups. One group receives a placebo shot while the other two receive one of two currently approved vaccines to prevent meningitis B. The vaccine groups received a second dose six months later.
In the beginning, throat swabs were taken In the study and at the one-year mark, the researchers want to see how protected the vaccinated teenagers are actually against meningitis B, compared with the control group. After that, the unvaccinated teenagers would also get the real shots (because they deserve protection). Researchers will also try to find out if the program offers herd immunity to the surrounding unvaccinated community.
"Participants not only get a vaccine that reduces the risk of meningitis, but also whether we can prevent the virus Other people translated & # 39; mellitus & # 39; into English: & # 39; # 39; at the University of Oxford, one of the many research institutions that participated in the study, […] the meninges, the protective layers that surround our brain and spinal cord, include high fever, headache and rash, although It can lead to full-blown sepsis and death.
Many things cause meningitis, but the most common bacterial culprit is called Neisseria meningitidis .There are 13 broad types or serogroups of N. Meningitidis known of which five can cause human illnesses (A, B, C, W and Y) .The bacteria like to nest in our throats and as many as one in ten people are having problems The problem starts when it finds its way somewhere in the body. It can be spread by close, prolonged contact with infected saliva or snot, a category that involves mating.
Since the 1970s, there is a vaccine that covers all non-B types of meningitis. But it was not until 2005, when a better non-B vaccine emerged, that countries like the USA recommended the shot for children aged 11 to 12 years and a booster shot at age 16.
The first meningitis B vaccine came on the market in 2015, but doctors in the US were reluctant to advocate it as a routine admission, citing concerns about its safety and that it might not be worth the general population too vaccinate, given the rarity of the disease. The UK has added it to its routine vaccination plan for children under 12 months, although it similarly decided not to recommend it to anyone at this time.
While cases of bacterial meningitis with only 350 cases are rarely diagnosed in the US in 2015, it remains an incredibly scary threat. Even with immediate medical care, 10 to 15 percent of patients die of it, while 11 to 19 percent develop long-term complications such as deafness or brain damage. And, according to infants, people aged 16 to 24 are the most vulnerable to getting it. In recent months, at least two outbreaks of bacterial meningitis have hit college campuses in the US, both caused by serogroup B, leading to major vaccine actions.
The TEAM study is expected to begin in April and continue recruitment for the next 18 months
[University of Oxford]